Dana Farber

Dana-Farber Cancer Institute, is a principal teaching affiliate of Harvard Medical School and an NCI-designated Comprehensive Cancer Center. Based in Boston, Dana-Farber is a world-renowned leader in adult and pediatric cancer treatment and scientific research.

Latest from Dana Farber

Young Women With Breast Cancer Who Undergo Mastectomy Report Lower Quality of Life

January 17, 2022

Article

A patient-reported outcome survey highlighted quality-of-life gaps in breast cancer survivorship.

Patients With HER2+ Breast Cancer and Brain Metastases Achieve Better OS With Tucatinib Triplet Regimen

January 09, 2022

Article

A triplet regimen of tucatinib, trastuzumab, and capecitabine helped patients with HER2-positive metastatic breast cancer and brain metastases live longer with reduced disease progression compared with trastuzumab and capecitabine alone.

Genomic Alterations in Primary Breast Cancer May Increase Risk of Secondary Uterine Cancer in Patients Receiving Tamoxifen

December 31, 2021

Article

PI3K-pathway mutations may predict an increased risk of secondary uterine cancer in patients receiving tamoxifen to treat primary breast cancer.

COVID-19 Vaccines May Be Less Effective in Patients with Lymphoid Malignancies

November 24, 2021

Article

Physicians urge patients with lymphoid malignancies to continue precautionary COVID-19 measures regardless of vaccination status.

Understanding Translocation RCC Biology, Genomic Drivers May Provide Answers Needed for Better Targeted Treatments Options

October 31, 2021

Article

An expert from Dana-Farber Cancer Institute comments on ongoing research in translocation RCC and next steps for research in this treatment space.

Could MRD Negativity Become A Suitable Surrogate Endpoint in Multiple Myeloma Trials?

September 05, 2021

Article

The prognostic value of minimal residual disease negativity in multiple myeloma may make it a suitable surrogate endpoint in clinical trials, according to a group of researchers.